SCHEMBL22363136

SCHEMBL22363136

O=CC1(NC(=O)O)CCC(F)(F)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13584680 0.86
SCHEMBL4129946 0.81
SCHEMBL22380385 0.75 CTSK (0.33)
SCHEMBL15859416 0.73
SCHEMBL4693128 0.73 MME (0.31)
SCHEMBL3093430 0.71 CYP2C19 (0.31)
SCHEMBL19744800 0.68
SCHEMBL2746734 0.68 LMNA (0.30)
SCHEMBL26543372 0.68
SCHEMBL16653661 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3927698-A1 AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2021-12-29 EP disclosed
US-20200268730-A1 AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES JANSSEN PHARMACEUTICA NV (BE) 2020-08-27 US disclosed